Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The research, funded by Parkinson's UK, reveals that an experimental drug, tasquinimod, originally developed for prostate cancer, may have the potential to treat Parkinson's disease.

Image taken by the team of Parkinson’s stem cell-derived neurons growing

The Oxford Parkinson's Disease Centre team, in a study led by Professor Richard Wade-Martins and Professor Caleb Webber, have found compelling evidence that an experimental cancer drug may have the potential to treat Parkinson's disease.

Their research, funded by Parkinson's UK, suggests that tasquinimod, a drug not yet on the market, works by interacting with a key protein inside brain cells called HDAC4. This interaction controls the activity of genes that may be critical in the development of Parkinson's. 

The team are using pioneering stem cell techniques to grow brain cells from skin cell samples, donated by both people with and without the condition.

 

More information is available on the Parkinson's UK website and the Parkinson's UK Research Blog

More detail is also available on The University of Oxford website.

Read the full Cell Stem Cell paper here.

Similar stories

Oxford Parkinson’s Disease Centre host the 2022 Oxford Parkinson’s Research Day

On Tuesday 29th November 2022, Professor Richard Wade-Martins and Professor Michele Hu from the Oxford Parkinson’s Disease Centre (OPDC) hosted the Oxford Parkinson’s Research Day at the Kavli Institute for Nanoscience Discovery, Dorothy Crowfoot Hodgkin Building, South Parks Road, Oxford.

Key cause of type 2 diabetes uncovered

Research led by Dr Elizabeth Haythorne and Professor Frances Ashcroft reveals high blood glucose reprograms the metabolism of pancreatic beta-cells in diabetes. They have discovered that glucose metabolites, rather than glucose itself, are key to the progression of type 2 diabetes. Glucose metabolites damage pancreatic beta-cell function, so they are unable to release enough of the hormone insulin. Reducing the rate at which glucose is metabolised, and these glucose metabolites build up, can prevent the effects of hyperglycaemia.

New study shows clinical symptoms for Alzheimer’s can be predicted in preclinical models

Establishing preclinical models of Alzheimer’s that reflect in-life clinical symptoms of each individual is a critically important goal, yet so far it has not been fully realised. A new collaborative study from the University of Oxford has demonstrated that clinical vulnerability to an abnormally abundant protein in Alzheimer’s brain is in fact reflected in individual patient induced pluripotent stem cell-derived cortical neurons.

Updating the circuit maps of the sympathetic neural network

A new review from Professor Ana Domingos’ lab and colleagues offers a fresh modern viewpoint on sympathetic neurons and their relation to immune cells and obesity.

New Pfizer grant paves the way to a better understanding of how body fat is controlled

Professor Ana Domingos has been awarded a highly competitive independent research grant from Pfizer to discover ‘the role of Sympathetic-associated Perineurial barrier Cells in obesity’.